Publications and presentations

The outcomes of our research are shared in leading journals and conferences. Below are some of our key publications that highlight recent research, and papers that have influenced policy and transfusion practice in Australia and around the world. Please refer to our PDF listing to see all publications from 2018 to present.

2025 highlights

Carrillo de Albornoz S, Zhang X, Arnolda R, MacPhail A, Irving A, Higgins AM, Wood EM, McQuilten ZK, Petrie D. Immunoglobulin use, survival, and infection outcomes in patients with chronic lymphocytic leukemia. Blood Advances. 2025 Oct 28;9(20):5367-5377. doi: 10.1182/bloodadvances.2025015867.

Mo A, Wood E, McQuilten Z. Platelet transfusion. Current Opinion in Hematology. 2025 Jan 1;32(1):14-21. doi: 10.1097/MOH.0000000000000843.

Mo A, Wood EM, Shortt J, McQuilten ZK. Red blood cell transfusion practice and cardiac comorbidities in patients with myelodysplastic syndromes. Transfusion. 2025 Oct;65(10):1803-1809. doi: 10.1111/trf.18391.

2024 highlights

McQuilten, ZK, et al. (2024). Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy. Blood Advances, 8(7), 1787-1795. doi:10.1182/bloodadvances.2023011231

Mo, A, et al. (2024). Rethinking the transfusion pathway in myelodysplastic syndromes: Study protocol for a novel randomized feasibility n-of-1 trial of weekly-interval red cell transfusion in myelodysplastic syndromes. Transfusion, 64(2):236-247. doi:10.1111/trf.17706

MacPhail, A, et al. (2024). Sepsis mortality among patients with haematological malignancy admitted to intensive care 2000-2022: a binational cohort study. Critical Care, 28(1), 148. doi:10.1186/s13054-024-04932-0

2023 highlights

Chai KL, et al. (2023). Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis. Blood Advances, 7(1), 20–31. doi: 10.1182/bloodadvances.2022008073

Stadler, E, et al. (2023). Monoclonal antibody levels and protection from COVID-19. Nature Communications, 14(1), 4545. doi:10.1038/s41467-023-40204-1

Lin, VS, et al. (2023). Definitions of massive transfusion in adults with critical bleeding: a systematic review. Critical Care, 27(1), 265. doi:10.1186/s13054-023-04537-z

2022 highlights

REMAP-CAP Investigators. (2022). Effect of Antiplatelet Therapy on Survival and Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA, 327(13), 1247–1259. doi: 10.1001/jama.2022.2910.

de Vos TW, et al. (2022). Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study. The Lancet. Haematology, 9(11), e844–e853. doi: 10.1016/S2352-3026(22)00243-5

McQuilten, Z, et al. (2022). Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR). British Journal of Haematology doi:10.1111/bjh.18324

2021 highlights

REMAP-CAP Investigators. (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. The New England Journal of Medicine, 385(9), 777–789. doi: 10.1056/NEJMoa2103417

REMAP-CAP Investigators. (2021). Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA, 326(17), 1690–1702. doi: 10.1001/jama.2021.18178

McQuilten Z, et al. (2021). Epidemiology of Massive Transfusion - A Common Intervention in Need of a Definition. Transfusion Medicine Reviews, 35(4), 73–79. doi: 10.1016/j.tmrv.2021.08.006

2020 highlights

Chai KL, et al. (2020). Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. The Cochrane Database of Systematic Reviews, 10, CD013600. doi: 10.1002/14651858.CD013600.pub3

Stanworth SJ, et al. (2020). Red cell transfusion in outpatients with myelodysplastic syndromes: a feasibility and exploratory randomised trial. British Journal of Haematology, 189(2), 279–290. doi: 10.1111/bjh.16347

Flint AWJ, et al. (2020). Preoperative identification of cardiac surgery patients at risk of receiving a platelet transfusion: The Australian Cardiac Surgery Platelet Transfusion (ACSePT) risk prediction tool. Transfusion, 60(10), 2272–2283. doi: 10.1111/trf.15990

2019 highlights

McQuilten ZK, et al. (2019). The cost of blood: a study of the total cost of red blood cell transfusion in patients with β-thalassemia using time-driven activity-based costing. Transfusion, 59(11), 3386–3395. doi: 10.1111/trf.15558

Mueller MM, et al. (2019). Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA, 321(10), 983–997. doi: 10.1001/jama.2019.0554

Irving  A, et al. (2019). Fresh Red Cells for Transfusion in Critically Ill Adults: An Economic Evaluation of the Standard Issue Transfusion Versus Fresher Red-Cell Use in Intensive Care (TRANSFUSE) Clinical Trial. Critical Care Medicine, 47(7), e572–e579. doi: 10.1097/CCM.0000000000003781

2018 highlights

McNeil JJ, et al. (2018). Effect of Aspirin on Cardiovascular Events and Bleeding in the Healthy Elderly. The New England Journal of Medicine, 379(16), 1509–1518. doi: 10.1056/NEJMoa1805819

Dyer C, et al. (2018). A multicentred study to validate a consensus bleeding assessment tool developed by the biomedical excellence for safer transfusion collaborative for use in patients with haematological malignancy. Vox Sanguinis, 113(3), 251–259. doi: 10.1111/vox.12627

Fox LC, et al. (2018). Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Internal Medicine Journal, 48(6), 624–636. doi: 10.1111/imj.13804